Edition:
India

Biofrontera AG (BFRA.OQ)

BFRA.OQ on NASDAQ Stock Exchange Capital Market

12.62USD
12 Jul 2018
Change (% chg)

-- (--)
Prev Close
$12.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,184
52-wk High
$17.87
52-wk Low
$11.25

Summary

Name Age Since Current Position

Ulrich Granzer

2016 Chairman of the Supervisory Board

Hermann Luebbert

61 2005 Chairman of the Management Board, Chief Executive Officer

Juergen Baumann

63 2016 Vice Chairman of the Supervisory Board

Thomas Schaffer

2013 Chief Financial Officer, Member of the Management Board

Christoph Duenwald

2016 Member of the Management Board, Chief Commercial Officer

John Borer

56 2016 Member of the Supervisory Board

Hansjoerg Plaggemars

47 2016 Member of the Supervisory Board

Mark Reeth

2016 Member of the Supervisory Board

Kevin Weber

57 2016 Member of the Supervisory Board

Biographies

Name Description

Ulrich Granzer

Dr. Ulrich Granzer is Chairman of the Supervisory Board of Biofrontera AG since June 1, 2016. He was Member of the Supervisory Board from 2003 to June 1, 2016. He is also Managing Director of Granzer Regulatory Consulting & Services. In addition, he serves as Member of the Advisory Board of immatics biotechnologies GmbH. He was formerly Head of Regulatory Affairs at Glaxo Wellcome, BASF Pharma and Bayer Pharma, and has experience in the field of drug approval and all aspects of drug development including clinical trials.

Hermann Luebbert

Prof. Dr. Hermann Luebbert, Ph.D. is Chairman of the Management Board and Chief Executive Officer at Biofrontera AG since 2005. After eight years of academic research at the Universitaet zu Koeln and the California Institute of Technology, he spent ten years gaining experience in global research management at Sandoz and Novartis Pharma AG, prior to establishing Biofrontera AG in 1997. Prof. Dr. Luebbert was awarded the habilitation at the ETH (Eidgenoessische Technische Hochschule) Zuerich and holds the chair of Animal Physiology at Ruhr-Universitaet Bochum. He studied Biology in Koeln, where he completed a Doctorate in Philosophy in 1984.

Juergen Baumann

Mr. Juergen Baumann is Vice Chairman of the Supervisory Board of Biofrontera AG since June 1, 2016. He was Chairman of the Supervisory Board at the Company from September 4, 2007 to June 1, 2016. He has been active in various positions for 29 years at Schwarz Pharma AG. When he joined Schwarz Pharma in 1978, his initial function was in the area of company-planning and -organization. Later, by then head of the Marketing Services area, he was first responsible for building the business in the East-German states and later he managed the Business Development and International Marketing section. From 1998 to 2000, he headed the business of Schwarz Pharma AG in Europe (except Germany). He has been Member of the Executive Board of Schwarz Pharma AG from March 2000 until April 2007, where he oversaw the European business and the export. He is also Member of the Supervisory Board at Riemser Arzneimittel AG.

Thomas Schaffer

Mr. Thomas Schaffer has been Chief Financial Officer, Member of the Management Board at Biofrontera AG since June 3, 2013. Mr. Schaffer will be responsible for Finance and Administration, Controlling and Investor Relation. Mr. Schaffer started his career in various functions in Finance and Controlling at Siemens Semiconductor, where he reached the position of Vice President and CFO of the Security & Chipcard ICs. After four years as Managing Director and CFO of Infineon Ventures GmbH, he continued as Vice President and CFO of the Specialty DRAM Division of Qimonda AG and became Managing Director of Qimonda Solar GmbH. CFO positions at Heptagon Oy, Finland/Switzerland, and Ubidyne Inc., Delaware, USA, completed his international experience. Mr. Schaffer played roles in reaching corporate milestones for the companies he worked for, including capital raises, debt financings, corporate restructurings, M&A, and IPOs.

Christoph Duenwald

Mr. Christoph Duenwald is Member of the Management Board, Chief Commercial Officer at Biofrontera AG since April 15, 2016. Previously he served as Chief Commercial Officer at the company since July 22, 2015 till April 15, 2016. He also held management positions at Bayer Healthcare and Allergan.

John Borer

Mr. John Borer is Member of the Supervisory Board of Biofrontera AG since June 1, 2016. He is the Senior Managing Director and Head of Investment Banking at the Benchmark Company, LLC. He was formerly the CEO and Head of Investment Banking at Rodman & Renshaw, and has held senior positions at Pacific Business Credit and Barclays American Business Credit. He holds a Doctor of Law degree (J.D.) from Loyola Law School in Los Angeles and Bachelor of Science in Agricultural Economics from University of California.

Hansjoerg Plaggemars

Mr. Hansjoerg Plaggemars is Member of the Supervisory Board of Biofrontera AG since June 1, 2016. He is a Member of the Management Board of Deutsche Balaton AG. He was formerly the Managing Director and Chief Financial Officer at CoCreate Software GmbH, KAMPA AG, Unister Holdings and Müller Holdings. Hansjörg is also a board member of Bolanta AG, Carus AG, Eurohaus Frankfurt AG, and Fidelitas Deutsche Industrie Holding AG, among others. He holds a degree in Business Administration from the Universitaet Bamberg.

Mark Reeth

Mr. Mark D. Reeth is Member of the Supervisory Board at Biofrontera AG since June 1, 2016. He is an independent consultant specializing in trends in the pharmaceutical industry. He has more than 25 years of experience in a variety of senior management, legal and compliance positions with U.S. based healthcare companies ranging from HMOs, pharmaceutical and medical device companies, such as NYLCare, Merck-Medco Managed Care, Bracco Diagnostics, Medicis Pharmaceuticals and Salix Pharmaceuticals. He holds a Doctor of Law degree (J.D.) and Master of Economics from Duke University.

Kevin Weber

Mr. Kevin Weber is Member of the Supervisory Board of Biofrontera AG since June 1, 2016. He is the Chief Executive Officer of Paraffin International Inc. He has extensive experience in marketing and global operations and strategy, and has held senior roles at Depomed, Hyperion Therapeutics, and Medicis Pharmaceuticals. Kevin is also a board member of the American Academy of Pain Management Foundation and the American Chronic Pain Association. He holds a B.A. in Management and Marketing from Western Michigan University.